Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine patch for cognitive impairment in multiple sclerosis
2008-007015-32Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Exelon patch with Placebo patch (2 arms). Primary endpoint: Change from baseline to week 16 in total recall score on the Selective Reminding Test. Started Mar 2009; status: completed.
02
Drugs
rivastigmine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-007015-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007015-32.